About

Thing
A patient is any recipient of health care services performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, psychologist, dentist, veterinarian, or other health care provider.
Patient
Definition
A patient is any recipient of health care services performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, psychologist, dentist, veterinarian, or other health care provider.
Patient
Patient
A patient is any recipient of health care services performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, psychologist, dentist, veterinarian, or other health care provider.

Pronunciation

English

Patient

Patient
SpellingPatient
Pronunciation[Patient]

Mentions

Prior to treatment, patients involved in the studies reported moderate to severe migraine pain, with symptoms such as nausea and sensitivity to light and sound. Results showed that a high percentage of patients were able to gain relief from their migraine pain, some in as little as two hours after treatment. The most common side effect reported was nausea and dry mouth.

In studies, the Dayvigo was found to statistically improve sleep onset and keep patients asleep,when compared to the placebo. Dayvigo was also not found to cause rebound insomnia, a common problem with some sleep medications. This describes worsened sleep compared to the baseline after drug discontinuation. There was also no evidence of withdrawal effects.

Japan-based drugmaker Eisai Co’s U.S. subsidiary announced on Sunday that it had received approval from the U.S. Food and Drug Administration for its insomnia treatment in adult patients.

The approval comes with FDA’s harshest warning that the drug is not for the treatment of patients with dementia-related psychosis.

The federal Food and Drug Administration has approved a gene therapy for a rare childhood disorder that is now the most expensive drug on the market. It costs $2.125 million per patient.

Palforzia is seen as an important test case for a new generation of therapies expected to transform how food allergies are treated. Doctors who have had few tools other than counseling their patients to assiduously avoid peanuts expect that other drugs will follow — additional drugs for the peanut allergy, as well as egg and tree nut allergies. Aimmune Therapeutics, which makes Palforzia, has several other food allergy treatments in its pipeline.

“Despite industry advancements, there are limited therapeutic options for treating patients with epithelioid sarcoma who struggle with high rates of recurrence and toxicities associated with currently used therapies,” said Gary K. Schwartz, M.D., chief of hematology and oncology at Columbia University and NewYork-Presbyterian Hospital, deputy director of the Herbert Irving Comprehensive Cancer Center, professor of oncology at Columbia University Vagelos College of Physicians and Surgeons and an investigator in Epizyme’s Phase 2 trial. “The TAZVERIK data from the ES cohort in Epizyme’s Phase 2 trial support its potential to provide clinically meaningful and durable responses, and tolerability for ES patients. This approval of TAZVERIK represents an important advancement in the treatment of patients with ES.”

Lannett Company (NYSE:LCI), a small-cap drug manufacturer, received FDA approval for Numbrino, the first branded drug in the company's 78-year history. The nasal spray will be marketed to doctors as a local anesthetic for minor surgeries around the nasal cavities of patients, but will not be available in retail pharmacies.

The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a clinical trial.

At month end, the company’s PUR1900 ("Pulmazole") received the fast track designation from the FDA. The proprietary product is an inhaled itraconazole antifungal candidate being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Constantini said the company is also working with the Léon Bérard Cancer Center in Lyon to use AI-based bioanalysis and bioinformatics to identify novel targets in immuno-oncology. It will focus on finding new pathways to address unmet needs for cancer patients.

PreludeDx has appointed Edwin Hendrick as the company's chief commercial officer. He has more than 30 years of related commercial experience and was most recently at Biocept. Before that, he was at Decipher Biosciences, formerly called GenomeDx, and at Plus Diagnostics. Laguna Hills, California-based PreludeDx's main product is the DCISionRT risk assessment test for patients with ductal carcinoma in situ.

DNAnexus CEO Richard Daly said that the new contract demonstrates his company's understanding of "FDA's evolving needs for data stewardship, security, and quality, and the increasing complexity of bioinformatics in regulatory review." He said that the expanded relationship will help PrecisionFDA "enhance the regulatory process and provide better options for patients and healthcare providers."

Comparing a patient’s DNA to reference data will allow doctors to find other people with similar DNA variants and see how they were diagnosed and treated. SolveBio’s founding team is currently focused on building a system that can integrate genomics data into diagnostic and research applications, which it will make available as an API.

The Internet is chock-full of medical advice and a significant number of doctors and patients use it to search for health information. However this information is often not easy to navigate or reliable, and most of the search is based on keywords and/or crowdsourced information.

More than a decade after the immense promise unleashed by the completion of Human Genome Project, precision medicine has struggled with its own “last mile.” Despite major leaps in the field as a whole, the technical work needed to integrate a patient’s genomic information into the day-to-day practice of medicine has lagged far behind.

Bempedoic acid is a once-a-day oral medication that will be commercially known as Nexletol. The FDA approved it for use with a healthy diet and the maximum dose of statins a patient tolerates. Studies show the new drug can reduce what doctors call low-density lipoprotein cholesterol, what you may know as LDL, the "bad" cholesterol that can lead to heart problems or strokes.

The Food and Drug Administration on Friday approved the first non-statin oral medication for high cholesterol in almost two decades, giving patients and doctors another weapon against heart disease, the No. 1 killer in the United States and around the world.

New to Cofactor?

Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.

See also: